KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$10.49 USD
+0.14 (1.35%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $10.49 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for KalVista Pharmaceuticals, Inc falls in the month of April.
All items in Millions except Per Share data.
4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | 4/30/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 149 | 166 | 249 | 68 | 101 |
Receivables | 17 | 14 | 10 | 17 | 11 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 13 | 5 | 4 | 3 |
Total Current Assets | 172 | 194 | 264 | 89 | 116 |
Net Property & Equipment | 3 | 2 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 183 | 204 | 272 | 93 | 118 |
Liabilities & Shareholders Equity | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | 4/30/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 4 | 2 | 2 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 7 | 7 | 5 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 10 |
Total Current Liabilities | 15 | 12 | 10 | 8 | 18 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 3 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 22 | 19 | 15 | 9 | 21 |
Shareholders Equity | 4/30/2023 | 4/30/2022 | 4/30/2021 | 4/30/2020 | 4/30/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 507 | 439 | 426 | 207 | 191 |
Retained Earnings | -343 | -250 | -168 | -122 | -92 |
Other Equity | -3 | -4 | -1 | -2 | -2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 161 | 185 | 257 | 84 | 97 |
Total Liabilities & Shareholder's Equity | 183 | 204 | 272 | 93 | 118 |
Total Common Equity | 161 | 185 | 257 | 84 | 97 |
Shares Outstanding | 34.10 | 24.50 | 24.40 | 17.80 | 17.20 |
Book Value Per Share | 4.72 | 7.55 | 10.54 | 4.71 | 5.62 |
Fiscal Year End for KalVista Pharmaceuticals, Inc falls in the month of April.
All items in Millions except Per Share data.
1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 | 1/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 76 | 103 | 123 | 149 | 172 |
Receivables | 23 | 20 | 19 | 17 | 12 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 5 | 8 | 6 | 9 |
Total Current Assets | 104 | 129 | 150 | 172 | 192 |
Net Property & Equipment | 2 | 3 | 3 | 3 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 114 | 139 | 160 | 183 | 203 |
Liabilities & Shareholders Equity | 1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 | 1/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 3 | 5 | 5 | 5 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 15 | 12 | 8 | 9 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 19 | 18 | 14 | 15 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 25 | 24 | 21 | 22 | 19 |
Shareholders Equity | 1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 | 1/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 517 | 514 | 511 | 507 | 505 |
Retained Earnings | -425 | -396 | -368 | -343 | -317 |
Other Equity | -3 | -3 | -3 | -3 | -4 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 89 | 114 | 139 | 161 | 184 |
Total Liabilities & Shareholder's Equity | 114 | 139 | 160 | 183 | 203 |
Total Common Equity | 89 | 114 | 139 | 161 | 184 |
Shares Outstanding | 34.50 | 34.40 | 34.20 | 34.10 | 34.10 |
Book Value Per Share | 2.57 | 3.33 | 4.07 | 4.72 | 5.41 |